Califon, NJ — September 8, 2010 — Dr. Cameron Durrant, Executive Chairman of Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL), will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13, 2010 in New York City. He will discuss ANAVEX 2-73, the company’s lead compound for the treatment of Alzheimer’s disease entering clinical trials, and the business case for Anavex.
Investors can register for free admission by following the instructions on the Rodman & Renshaw web site:
Journalists, analysts, industry executives and other high-level conference attendees are invited to contact us at firstname.lastname@example.org to see Dr. Durrant’s presentation and to arrange to meet with Dr. Durrant for a one-on-one discussion. A webcast of the presentation will also be available on the ANAVEX and the conference web sites.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological and cancer diseases. The company’s proprietary SIGMACEPTOR™ Discovery Platform involves the rational design of drug compounds that are targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.
ANAVEX’s SIGMACEPTOR™-N program involves the development of novel drug candidates that target neurological and neurodegenerative diseases (Alzheimer’s disease, epilepsy, depression and pain). The company’s lead drug candidates exhibit high affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated anti-amnesic and neuroprotective properties.
ANAVEX is a publically traded company under the symbol “AVXL”.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file an IND, an IMPD or commence clinical studies. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development